| scholarly article | Q13442814 |
| P50 | author | Jeff Longmate | Q30792585 |
| David R Gandara | Q73567194 | ||
| P2093 | author name string | Paul H Gumerlock | |
| Primo N Lara | |||
| James H Doroshow | |||
| Przemyslaw Twardowski | |||
| Frederick J Meyers | |||
| Christopher Ruel | |||
| Karen Giselle Chee | |||
| Carl R Gray | |||
| Regina Gandour Edwards | |||
| P2860 | cites work | Humanization of an anti-p185HER2 antibody for human cancer therapy | Q24561842 |
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
| Circulating tumor markers in breast cancer: accepted utilities and novel prospects | Q33538453 | ||
| Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2). | Q34134997 | ||
| Current strategies in the management of hormone refractory prostate cancer | Q35145701 | ||
| Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic | Q36517425 | ||
| p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor | Q36767887 | ||
| HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial | Q38455547 | ||
| HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas | Q38474138 | ||
| A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. | Q41615181 | ||
| Expression of c-erb B-2/neu proto-oncogene in human prostatic cancer tissues and cell lines | Q41649869 | ||
| Cancer statistics, 2003. | Q43729872 | ||
| Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a requested for a standardized, organ specific methodology | Q44168590 | ||
| Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer. | Q53511518 | ||
| Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. | Q53622998 | ||
| Her-2-neu expression and progression toward androgen independence in human prostate cancer. | Q53800928 | ||
| Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis | Q72237384 | ||
| HER2/neu expression in cancer: the pathologist as diagnostician or prophet? | Q73697270 | ||
| HER2 protein expression and gene amplification in androgen-independent prostate cancer | Q74317132 | ||
| Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer | Q77995576 | ||
| Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer | Q78009900 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | California | Q99 |
| trastuzumab | Q412616 | ||
| docetaxel | Q420436 | ||
| prostate carcinoma | Q18553829 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 2125-2131 | |
| P577 | publication date | 2004-05-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial | |
| P478 | volume | 100 |
| Q57142029 | Q57142029 |
| Q39772849 | A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer |
| Q36785721 | Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment |
| Q36760292 | Advances in prostate cancer immunotherapies |
| Q36731130 | Biologic agents as adjunctive therapy for prostate cancer: a rationale for use with androgen deprivation |
| Q36786062 | Cancer dormancy: lessons from a B cell lymphoma and adenocarcinoma of the prostate |
| Q79954721 | Close association between HER-2 amplification and overexpression in human tumors of non-breast origin |
| Q89847014 | Combined targeting of EGFR and HER2 against prostate cancer stem cells |
| Q39398599 | Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts |
| Q92826438 | Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase |
| Q35269318 | Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3 |
| Q41768007 | ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer |
| Q33626875 | Frequency of HER2/neu overexpression in adenocarcinoma of the gastrointestinal system |
| Q36374578 | Genomic and epigenomic alterations in prostate cancer. |
| Q36409209 | Her-2 targeted therapy: beyond breast cancer and trastuzumab |
| Q45288943 | High Nr-CAM expression is associated with favorable phenotype and late PSA recurrence in prostate cancer treated by prostatectomy |
| Q44994966 | High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer |
| Q36830104 | Hormone-refractory prostate cancer: where are we going? |
| Q42018419 | Imaging agents for in vivo molecular profiling of disseminated prostate cancer: Cellular processing of [(111)In]-labeled CHX-A″DTPA-trastuzumab and anti-HER2 ABY-025 Affibody in prostate cancer cell lines |
| Q43867243 | Immunohistochemical expression of PDGFR, VEGF-C, and proteins of the mToR pathway before and after androgen deprivation therapy in prostate carcinoma: significant decrease after treatment. |
| Q42738512 | Immunologic biomarkers in prostate cancer: the AE37 paradigm |
| Q54707393 | Improving the efficacy of targeted trials by multiple-marker analysis in castration-resistant prostate cancer. |
| Q37765470 | Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. |
| Q40268472 | Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo |
| Q33416583 | Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures |
| Q35157412 | Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients. |
| Q43199031 | Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms |
| Q38174595 | Profiling serum HER-2/NEU in prostate cancer |
| Q79808747 | Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer |
| Q37800698 | Risk of cardiac dysfunction with trastuzumab in breast cancer patients: A meta-analysis |
| Q37575815 | Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy |
| Q51753573 | Significant prognostic factor of immunohistochemical HER‐2 expression using initial prostate biopsy specimens with M1b prostate cancer |
| Q37968256 | Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer |
| Q34985562 | Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block |
| Q44947041 | The role of immunotherapy in prostate cancer: an overview of current approaches in development. |
| Q36230812 | Use of protein array technology to investigate receptor tyrosine kinases activated in hepatocellular carcinoma |
| Q35585704 | VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy |
| Q80697262 | [Role of androgen receptors in hormone-refractory prostate cancer: molecular basics and experimental therapy approaches] |
Search more.